Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Air Products & Chemicals, Inc.APD · Entity 2983 | Director | September 30, 2020 | October 01, 2020 |
| NOVAVAX INCNVAX · Entity 4632 | Director | June 18, 2026 | June 23, 2026 |
| VERTEX PHARMACEUTICALS INC / MAVRTX · Entity 2875 | Director | May 01, 2023 | May 03, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Air Products & Chemicals, Inc.
Report date September 30, 2020 · Filed October 01, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Phantom StockSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 42,813.6292 |
Reported balance
After 2020-09-30 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2020-09-30 · Grant · Acquired 194.3437 · Balance 42,813.6292 F1: Phantom deferred stock units (Units) acquired under the Air Products Stock Account of the issuer's Deferred Compensation Program for Directors, under the Company's Long-Term Incentive Plan. F2: Not applicable to this security F3: These Units are payable in the form of shares of common stock equal in number to the Units, at the time elected by the reporting person, which is generally after service on the Company's Board of Directors ends. Units may be paid in a lump sum or up to ten installments as elected by the reporting person in advance. |
Filing footnotes · ownership attribution and instrument terms
F1: Phantom deferred stock units (Units) acquired under the Air Products Stock Account of the issuer's Deferred Compensation Program for Directors, under the Company's Long-Term Incentive Plan.
F2: Not applicable to this security
F3: These Units are payable in the form of shares of common stock equal in number to the Units, at the time elected by the reporting person, which is generally after service on the Company's Board of Directors ends. Units may be paid in a lump sum or up to ten installments as elected by the reporting person in advance.
NOVAVAX INC
Report date June 18, 2026 · Filed June 23, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 44,468 |
Reported balance
After 2026-06-20 transaction · row 1
1 source rowRow 1 · 2026-06-20 · Exercise / conversion · Acquired 18,880 · Balance 44,468 F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Novavax, Inc. (the "Company") common stock. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.13 · Expires 2036-06-18 | Direct | 21,270 |
Reported balance
After 2026-06-18 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-18 · Grant · Acquired 21,270 · Balance 21,270 F2: One hundred percent (100%) of the shares subject to this option grant under the Amended and Restated 2015 Stock Incentive Plan, as amended, will vest on the first anniversary of the June 18, 2026 grant date subject to continued service on the Company's Board of Directors through the vesting date. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 14,180 |
Reported balance
After 2026-06-18 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-06-18 · Grant · Acquired 14,180 · Balance 14,180 F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Novavax, Inc. (the "Company") common stock. F3: One hundred percent (100%) of the RSUs subject to this grant under the Company's Amended and Restated 2015 Stock Incentive Plan, as amended, will vest on the first anniversary of the June 18, 2026 grant date subject to continued service on the Company's Board of Directors through the vesting date. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-06-20 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-06-20 · Exercise / conversion · Disposed 18,880 · Balance 0 F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Novavax, Inc. (the "Company") common stock. F4: One hundred percent (100%) of the RSUs subject to this grant under the Company's Amended and Restated 2015 Stock Incentive Plan, as amended, vested on the first anniversary of the June 20, 2025 grant date subject to continued service on the Company's Board of Directors through the vesting date |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Novavax, Inc. (the "Company") common stock.
F2: One hundred percent (100%) of the shares subject to this option grant under the Amended and Restated 2015 Stock Incentive Plan, as amended, will vest on the first anniversary of the June 18, 2026 grant date subject to continued service on the Company's Board of Directors through the vesting date.
F3: One hundred percent (100%) of the RSUs subject to this grant under the Company's Amended and Restated 2015 Stock Incentive Plan, as amended, will vest on the first anniversary of the June 18, 2026 grant date subject to continued service on the Company's Board of Directors through the vesting date.
F4: One hundred percent (100%) of the RSUs subject to this grant under the Company's Amended and Restated 2015 Stock Incentive Plan, as amended, vested on the first anniversary of the June 20, 2025 grant date subject to continued service on the Company's Board of Directors through the vesting date
VERTEX PHARMACEUTICALS INC / MA
Report date May 01, 2023 · Filed May 03, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $342.73 · Expires 2033-04-30 | Direct | 3,481 |
Reported balance
After 2023-05-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-05-01 · Grant · Acquired 3,481 · Balance 3,481 F1: Fully vested. |
Filing footnotes · ownership attribution and instrument terms
F1: Fully vested.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
AMICUS THERAPEUTICS, INC.
Report date April 27, 2026 · Filed April 27, 2026
Section 16 reporting ended · disclosed 2026-04-27. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2026-04-27 transaction · row 1
1 source rowRow 1 · 2026-04-27 · Disposition to issuer · Disposed 94,631 · Balance 0 F1: The reported securities were disposed of in connection with consummation of the acquisition of the Issuer by BioMarin Pharmaceutical Inc. (the "Merger"), which included 31,000 shares of Common Stock and 63,631 restricted stock units (which vested in full in connection with consummation of the Merger). |
| Stock Options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.71 · Expires 2026-06-09 | Direct | 0 |
Reported balance
After 2026-04-27 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-04-27 · Disposition to issuer · Disposed 20,000 · Balance 0 F2: In connection with consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment equal to (a) the excess of (i) $14.50 per share over (ii) the exercise price payable per share, multiplied by (b) the total number of shares subject to such Option. F3: Each Option was fully vested. |
| Stock Options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.60 · Expires 2027-06-13 | Direct | 0 |
Reported balance
After 2026-04-27 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-04-27 · Disposition to issuer · Disposed 16,236 · Balance 0 F2: In connection with consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment equal to (a) the excess of (i) $14.50 per share over (ii) the exercise price payable per share, multiplied by (b) the total number of shares subject to such Option. F3: Each Option was fully vested. |
| Stock Options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.00 · Expires 2029-06-27 | Direct | 0 |
Reported balance
After 2026-04-27 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-04-27 · Disposition to issuer · Disposed 19,473 · Balance 0 F2: In connection with consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment equal to (a) the excess of (i) $14.50 per share over (ii) the exercise price payable per share, multiplied by (b) the total number of shares subject to such Option. F3: Each Option was fully vested. |
| Stock Options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.81 · Expires 2030-06-04 | Direct | 0 |
Reported balance
After 2026-04-27 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-04-27 · Disposition to issuer · Disposed 18,574 · Balance 0 F2: In connection with consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment equal to (a) the excess of (i) $14.50 per share over (ii) the exercise price payable per share, multiplied by (b) the total number of shares subject to such Option. F3: Each Option was fully vested. |
| Stock Options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.71 · Expires 2031-06-10 | Direct | 0 |
Reported balance
After 2026-04-27 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-04-27 · Disposition to issuer · Disposed 36,111 · Balance 0 F2: In connection with consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment equal to (a) the excess of (i) $14.50 per share over (ii) the exercise price payable per share, multiplied by (b) the total number of shares subject to such Option. F3: Each Option was fully vested. |
| Stock Options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.55 · Expires 2032-06-09 | Direct | 0 |
Reported balance
After 2026-04-27 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2026-04-27 · Disposition to issuer · Disposed 45,423 · Balance 0 F2: In connection with consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment equal to (a) the excess of (i) $14.50 per share over (ii) the exercise price payable per share, multiplied by (b) the total number of shares subject to such Option. F3: Each Option was fully vested. |
| Stock Options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.62 · Expires 2033-06-08 | Direct | 0 |
Reported balance
After 2026-04-27 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2026-04-27 · Disposition to issuer · Disposed 30,474 · Balance 0 F2: In connection with consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment equal to (a) the excess of (i) $14.50 per share over (ii) the exercise price payable per share, multiplied by (b) the total number of shares subject to such Option. F3: Each Option was fully vested. |
| Stock Options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.27 · Expires 2034-06-06 | Direct | 0 |
Reported balance
After 2026-04-27 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2026-04-27 · Disposition to issuer · Disposed 42,467 · Balance 0 F2: In connection with consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment equal to (a) the excess of (i) $14.50 per share over (ii) the exercise price payable per share, multiplied by (b) the total number of shares subject to such Option. F3: Each Option was fully vested. |
| Stock Options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.96 · Expires 2035-06-05 | Direct | 0 |
Reported balance
After 2026-04-27 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2026-04-27 · Disposition to issuer · Disposed 74,872 · Balance 0 F2: In connection with consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment equal to (a) the excess of (i) $14.50 per share over (ii) the exercise price payable per share, multiplied by (b) the total number of shares subject to such Option. F4: Each Option vested in full in connection with consummation of the Merger. |
Filing footnotes · ownership attribution and instrument terms
F1: The reported securities were disposed of in connection with consummation of the acquisition of the Issuer by BioMarin Pharmaceutical Inc. (the "Merger"), which included 31,000 shares of Common Stock and 63,631 restricted stock units (which vested in full in connection with consummation of the Merger).
F2: In connection with consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment equal to (a) the excess of (i) $14.50 per share over (ii) the exercise price payable per share, multiplied by (b) the total number of shares subject to such Option.
F3: Each Option was fully vested.
F4: Each Option vested in full in connection with consummation of the Merger.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 31, 2019 Filed Jan 3, 2020 17:22 UTC | Air Products & Chemicals, Inc. APD · Entity 2983 | GrantPhantom Stock · Derivative | 203.6312 | $235.33 Strike: $0.00 | $47,920.53 |
DisclosureSEC source: 0001225208-20-000143 · doc4.xml · derivative · entry 1 MCGLYNN MARGARET G · CIK 0001215126 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,514.4221 Underlying: Common Stock · 203.6312 shares Expires not disclosed F1 · security: Phantom deferred stock units (Units) acquired under the Air Products Stock Account of the issuer's Deferred Compensation Program for Directors, under the Company's Long-Term Incentive Plan. F2 · derivative.exercise_price: Not applicable to this security F3 · derivative.exercise_date: These Units are payable in the form of shares of common stock equal in number to the Units, at the time elected by the reporting person, which is generally after service on the Company's Board of Directors ends. Units may be paid in a lump sum or up to ten installments as elected by the reporting person in advance. F3 · derivative.expiration_date: These Units are payable in the form of shares of common stock equal in number to the Units, at the time elected by the reporting person, which is generally after service on the Company's Board of Directors ends. Units may be paid in a lump sum or up to ten installments as elected by the reporting person in advance. Read SEC document |
| November 26, 2019 Filed Nov 27, 2019 15:58 UTC | Air Products & Chemicals, Inc. APD · Entity 2983 | GrantPhantom Stock · Derivative | 3,973.266 | Not disclosed Strike: $0.00 | Not disclosed |
DisclosureSEC source: 0001225208-19-014981 · doc4.xml · derivative · entry 1 MCGLYNN MARGARET G · CIK 0001215126 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,310.7909 Underlying: Common Stock · 3,973.266 shares Expires not disclosed F1 · security: Phantom deferred stock units (Units) acquired under the Air Products Stock Account of the Air Products and Chemicals, Inc. (the Company) Deferred Compensation Program for Directors under the Company's Long-Term Incentive Plan (the Plan). F2 · shares: The amount reported reflects the conversion of the balance of Versum Materials, Inc. (Versum) deferred stock units (the Versum Units) held in the reporting person's Air Products Stock Account to Units as a result of the acquisition of Versum by Merck KGaA on October 7, 2019. The number of Units credited was calculated based on the closing price of the Company's common stock on October 7, 2019 of $213.96. F2 · price: The amount reported reflects the conversion of the balance of Versum Materials, Inc. (Versum) deferred stock units (the Versum Units) held in the reporting person's Air Products Stock Account to Units as a result of the acquisition of Versum by Merck KGaA on October 7, 2019. The number of Units credited was calculated based on the closing price of the Company's common stock on October 7, 2019 of $213.96. F3 · derivative.exercise_date: Not applicable to this security. F3 · derivative.expiration_date: Not applicable to this security. F4 · balance_after: The amount reported includes 91.7491 Units that were credited as an adjustment to the reporting person's Air Products Stock Account to reconcile minor discrepancies the Company identified in a review of its administration of the Plan. Read SEC document |
| November 18, 2019 Filed Nov 20, 2019 21:10 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GiftCommon Stock | 239 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-057431 · doc4.xml · nonDerivative · entry 1 MCGLYNN MARGARET G · CIK 0001215126 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,885 F1 · shares: This transaction represents a gift/charitable donation effective November 18, 2019, in which no value was received in return. Read SEC document |
| October 22, 2019 Filed Oct 24, 2019 23:26 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $72.14 | $0.00 |
DisclosureSEC source: 0001209191-19-053941 · doc4.xml · derivative · entry 3 MCGLYNN MARGARET G · CIK 0001215126 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,000 shares Expires 2024-05-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Fully vested. Read SEC document |
| October 22, 2019 Filed Oct 24, 2019 23:26 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 20,000 | $190.00 | $3,800,000.00 |
DisclosureSEC source: 0001209191-19-053941 · doc4.xml · nonDerivative · entry 2 MCGLYNN MARGARET G · CIK 0001215126 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,124 F1 · kind: Transaction made pursuant to Ms. McGlynn's company-approved trading plan under Rule 10b5-1. Read SEC document |
| October 22, 2019 Filed Oct 24, 2019 23:26 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 20,000 | $72.14 | $1,442,800.00 |
DisclosureSEC source: 0001209191-19-053941 · doc4.xml · nonDerivative · entry 1 MCGLYNN MARGARET G · CIK 0001215126 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,124 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 30, 2019 Filed Oct 2, 2019 18:18 UTC | Air Products & Chemicals, Inc. APD · Entity 2983 | GrantPhantom Stock · Derivative | 199.4716 | $221.86 Strike: $0.00 | $44,254.77 |
DisclosureSEC source: 0001225208-19-012998 · doc4.xml · derivative · entry 1 MCGLYNN MARGARET G · CIK 0001215126 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,245.7758 Underlying: Common Stock · 199.4716 shares Expires not disclosed F1 · security: Phantom deferred stock units (Units) acquired under the Air Products Stock Account of the issuer's Deferred Compensation Program for Directors, under the Company's Long-Term Incentive Plan. F2 · derivative.exercise_price: Not applicable to this security F3 · derivative.exercise_date: These Units are payable in the form of shares of common stock equal in number to the Units, at the time elected by the reporting person, which is generally after service on the Company's Board of Directors ends. Units may be paid in a lump sum or up to ten installments as elected by the reporting person in advance. F3 · derivative.expiration_date: These Units are payable in the form of shares of common stock equal in number to the Units, at the time elected by the reporting person, which is generally after service on the Company's Board of Directors ends. Units may be paid in a lump sum or up to ten installments as elected by the reporting person in advance. Read SEC document |
| August 13, 2019 Filed Aug 15, 2019 20:11 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $81.54 | $0.00 |
DisclosureSEC source: 0001209191-19-046107 · doc4.xml · derivative · entry 3 MCGLYNN MARGARET G · CIK 0001215126 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2023-05-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Fully vested. Read SEC document |
| August 13, 2019 Filed Aug 15, 2019 20:11 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 10,000 | $185.00 | $1,850,000.00 |
DisclosureSEC source: 0001209191-19-046107 · doc4.xml · nonDerivative · entry 2 MCGLYNN MARGARET G · CIK 0001215126 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,124 F1 · kind: Transaction made pursuant to Ms. McGlynn's company approved trading plan under Rule 10b5-1. Read SEC document |
| August 13, 2019 Filed Aug 15, 2019 20:11 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 10,000 | $81.54 | $815,400.00 |
DisclosureSEC source: 0001209191-19-046107 · doc4.xml · nonDerivative · entry 1 MCGLYNN MARGARET G · CIK 0001215126 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,124 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 01, 2019 Filed Jul 2, 2019 20:11 UTC | Air Products & Chemicals, Inc. APD · Entity 2983 | GrantPhantom Stock · Derivative | 194.5008 | $226.37 Strike: $0.00 | $44,029.15 |
DisclosureSEC source: 0001225208-19-009824 · doc4.xml · derivative · entry 1 MCGLYNN MARGARET G · CIK 0001215126 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,046.3042 Underlying: Common Stock · 194.5008 shares Expires not disclosed F1 · security: Phantom deferred stock units (Units) acquired under the Air Products Stock Account of the issuer's Deferred Compensation Program for Directors, under the Company's Long-Term Incentive Plan. F2 · derivative.exercise_price: Not applicable to this security F3 · derivative.exercise_date: These Units are payable in the form of shares of common stock equal in number to the Units, at the time elected by the reporting person, which is generally after service on the Company's Board of Directors ends. Units may be paid in a lump sum or up to ten installments as elected by the reporting person in advance. F3 · derivative.expiration_date: These Units are payable in the form of shares of common stock equal in number to the Units, at the time elected by the reporting person, which is generally after service on the Company's Board of Directors ends. Units may be paid in a lump sum or up to ten installments as elected by the reporting person in advance. Read SEC document |
| June 27, 2019 Filed Jul 1, 2019 21:00 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | GrantStock Options (right to buy) · Derivative | 19,473 | $0.00 Strike: $12.00 | $0.00 |
DisclosureSEC source: 0001209191-19-039766 · doc4.xml · derivative · entry 2 MCGLYNN MARGARET G · CIK 0001215126 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,473 Underlying: Common Stock · 19,473 shares Expires 2029-06-27 F2 · derivative.exercise_date: One hundred percent of the shares subject to this option will vest and become exercisable on the date of the annual meeting of the stockholders of the issuer to be held in 2020. Read SEC document |
| June 27, 2019 Filed Jul 1, 2019 21:00 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | GrantCommon Stock | 6,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-039766 · doc4.xml · nonDerivative · entry 1 MCGLYNN MARGARET G · CIK 0001215126 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,064 F1 · shares: The Restricted Stock Units will vest one year after date of grant and vested shares will be payable in common stock. One (1) Restricted Stock Unit is the equivalent of one (1) share of Amicus Therapeutics, Inc. common stock. Read SEC document |
| June 01, 2019 Filed Jun 4, 2019 20:15 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantDeferred Stock Units · Derivative | 1,801 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-19-034236 · doc4.xml · derivative · entry 3 MCGLYNN MARGARET G · CIK 0001215126 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,989 Underlying: Common Stock · 1,801 shares Expires not disclosed F3 · derivative.exercise_price: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Ms. McGlynn's service on our board of directors, (ii) a change of control of our company and (iii) Ms. McGlynn's disability or death. F1 · price: Upon the vesting of restricted stock units granted to Ms. McGlynn on June 1, 2018, Ms. McGlynn deferred the receipt of 1,801 shares of common stock and received instead 1,801 deferred stock units pursuant to the Company's deferred compensation plan. As a result, Ms. McGlynn is reporting the disposition of 1,801 shares of common stock in exchange for an equal number of deferred stock units. F3 · derivative.exercise_date: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Ms. McGlynn's service on our board of directors, (ii) a change of control of our company and (iii) Ms. McGlynn's disability or death. F3 · derivative.expiration_date: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Ms. McGlynn's service on our board of directors, (ii) a change of control of our company and (iii) Ms. McGlynn's disability or death. Read SEC document |
| June 01, 2019 Filed Jun 4, 2019 20:15 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantStock Option (Right to Buy) · Derivative | 6,659 | $0.00 Strike: $168.04 | $0.00 |
DisclosureSEC source: 0001209191-19-034236 · doc4.xml · derivative · entry 2 MCGLYNN MARGARET G · CIK 0001215126 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,659 Underlying: Common Stock · 6,659 shares Expires 2029-05-31 F2 · derivative.exercise_date: Fully vested. Read SEC document |
| June 01, 2019 Filed Jun 4, 2019 20:15 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Disposition to issuerCommon Stock | 1,801 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-19-034236 · doc4.xml · nonDerivative · entry 1 MCGLYNN MARGARET G · CIK 0001215126 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,124 F1 · price: Upon the vesting of restricted stock units granted to Ms. McGlynn on June 1, 2018, Ms. McGlynn deferred the receipt of 1,801 shares of common stock and received instead 1,801 deferred stock units pursuant to the Company's deferred compensation plan. As a result, Ms. McGlynn is reporting the disposition of 1,801 shares of common stock in exchange for an equal number of deferred stock units. Read SEC document |
| April 01, 2019 Filed Apr 2, 2019 18:43 UTC | Air Products & Chemicals, Inc. APD · Entity 2983 | GrantPhantom Stock · Derivative | 217.317 | $186.51 Strike: $0.00 | $40,531.79 |
DisclosureSEC source: 0001225208-19-006020 · doc4.xml · derivative · entry 1 MCGLYNN MARGARET G · CIK 0001215126 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,851.8034 Underlying: Common Stock · 217.317 shares Expires not disclosed F1 · security: Phantom deferred stock units (Units) acquired under the Air Products Stock Account of the issuer's Deferred Compensation Program for Directors, under the Company's Long-Term Incentive Plan. The number of Units acquired by the reporting person was determined on April 1, 2019. F2 · derivative.exercise_price: Not applicable to this security F3 · derivative.exercise_date: These Units are payable in the form of shares of common stock equal in number to the Units, at the time elected by the reporting person, which is generally after service on the Company's Board of Directors ends. Units may be paid in a lump sum or up to ten installments as elected by the reporting person in advance. F3 · derivative.expiration_date: These Units are payable in the form of shares of common stock equal in number to the Units, at the time elected by the reporting person, which is generally after service on the Company's Board of Directors ends. Units may be paid in a lump sum or up to ten installments as elected by the reporting person in advance. Read SEC document |
| January 24, 2019 Filed Jan 25, 2019 18:28 UTC | Air Products & Chemicals, Inc. APD · Entity 2983 | GrantPhantom Stock · Derivative | 952 | $157.71 Strike: $0.00 | $150,139.92 |
DisclosureSEC source: 0001225208-19-001268 · doc4.xml · derivative · entry 1 MCGLYNN MARGARET G · CIK 0001215126 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,634.4864 Underlying: Common Stock · 952 shares Expires not disclosed F1 · security: Phantom deferred stock units (Units) acquired under the Air Products Stock Account of the issuer's Deferred Compensation Program for Directors, of the Company's Long-Term Incentive Plan (the Plan). F2 · derivative.exercise_price: Not applicable to this security F3 · derivative.exercise_date: These units are payable in the form of shares of common Stock equal in number to the units, at the time elected by the reporting person, which is generally after service on the issuer's Board of Directors ends. Units may be paid in a lump sum or up to ten installments as elected by the reporting person in advance. F3 · derivative.expiration_date: These units are payable in the form of shares of common Stock equal in number to the units, at the time elected by the reporting person, which is generally after service on the issuer's Board of Directors ends. Units may be paid in a lump sum or up to ten installments as elected by the reporting person in advance. Read SEC document |
| December 31, 2018 Filed Jan 2, 2019 20:30 UTC | Air Products & Chemicals, Inc. APD · Entity 2983 | GrantPhantom Stock · Derivative | 256.4978 | $156.92 Strike: $0.00 | $40,249.63 |
DisclosureSEC source: 0001225208-19-000059 · doc4.xml · derivative · entry 1 MCGLYNN MARGARET G · CIK 0001215126 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,682.4864 Underlying: Common Stock · 256.4978 shares Expires not disclosed F1 · security: Phantom deferred stock units (Units) acquired under the Air Products Stock Account of the issuer's Deferred Compensation Program for Directors, of the Company's Long-Term Incentive Plan (the Plan). F2 · derivative.exercise_price: Not applicable to this security F3 · derivative.exercise_date: These units are payable in the form of shares of common Stock equal in number to the units, at the time elected by the reporting person, which is generally after service on the issuer's Board of Directors ends. Units may be paid in a lump sum or up to ten installments as elected by the reporting person in advance. F3 · derivative.expiration_date: These units are payable in the form of shares of common Stock equal in number to the units, at the time elected by the reporting person, which is generally after service on the issuer's Board of Directors ends. Units may be paid in a lump sum or up to ten installments as elected by the reporting person in advance. Read SEC document |
| September 30, 2018 Filed Oct 1, 2018 14:14 UTC | Air Products & Chemicals, Inc. APD · Entity 2983 | GrantPhantom Stock · Derivative | 236.4084 | $167.80 Strike: $0.00 | $39,669.33 |
DisclosureSEC source: 0001225208-18-013838 · doc4.xml · derivative · entry 1 MCGLYNN MARGARET G · CIK 0001215126 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,425.9886 Underlying: Common Stock · 236.4084 shares Expires not disclosed F1 · security: Phantom deferred stock units (Units) acquired under the Air Products Stock Account of the issuer's Deferred Compensation Program for Directors, of the Company's Long-Term Incentive Plan (the Plan). F2 · derivative.exercise_price: Not applicable to this security F3 · derivative.exercise_date: These units are payable in the form of shares of common Stock equal in number to the units, at the time elected by the reporting person, which is generally after service on the issuer's Board of Directors ends. Units may be paid in a lump sum or up to ten installments as elected by the reporting person in advance. F3 · derivative.expiration_date: These units are payable in the form of shares of common Stock equal in number to the units, at the time elected by the reporting person, which is generally after service on the issuer's Board of Directors ends. Units may be paid in a lump sum or up to ten installments as elected by the reporting person in advance. Read SEC document |
| June 30, 2018 Filed Jul 2, 2018 18:19 UTC | Air Products & Chemicals, Inc. APD · Entity 2983 | GrantPhantom Stock · Derivative | 253.8675 | $155.16 Strike: $0.00 | $39,390.08 |
DisclosureSEC source: 0001225208-18-011012 · doc4.xml · derivative · entry 1 MCGLYNN MARGARET G · CIK 0001215126 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,189.5802 Underlying: Common Stock · 253.8675 shares Expires not disclosed F1 · security: Phantom deferred stock units (Units) acquired under the Air Products Stock Account of the issuer's Deferred Compensation Program for Directors, of the Company's Long-Term Incentive Plan (the Plan). F2 · derivative.exercise_price: Not applicable to this security F3 · derivative.exercise_date: These units are payable in the form of shares of common Stock equal in number to the units, at the time elected by the reporting person, which is generally after service on the issuer's Board of Directors ends. Units may be paid in a lump sum or up to ten installments as elected by the reporting person in advance. F3 · derivative.expiration_date: These units are payable in the form of shares of common Stock equal in number to the units, at the time elected by the reporting person, which is generally after service on the issuer's Board of Directors ends. Units may be paid in a lump sum or up to ten installments as elected by the reporting person in advance. Read SEC document |
| June 07, 2018 Filed Jun 11, 2018 20:48 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | GrantStock Options (right to buy) · Derivative | 8,912 | $0.00 Strike: $16.23 | $0.00 |
DisclosureSEC source: 0001209191-18-037001 · doc4.xml · derivative · entry 2 MCGLYNN MARGARET G · CIK 0001215126 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,912 Underlying: Common Stock · 8,912 shares Expires 2028-06-07 F2 · derivative.exercise_date: One hundred percent of the shares subject to this option will vest and become exercisable on the date of the annual meeting of the stockholders of the issuer to be held in 2019. Read SEC document |
| June 07, 2018 Filed Jun 11, 2018 20:48 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | GrantCommon Stock | 3,081 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-037001 · doc4.xml · nonDerivative · entry 1 MCGLYNN MARGARET G · CIK 0001215126 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,895 F1 · shares: The Restricted Stock Units will vest one year after date of grant and vested shares will be payable in common stock. One (1) Restricted Stock Unit is the equivalent of one (1) share of Amicus Therapeutics, Inc. common stock. Read SEC document |
| June 01, 2018 Filed Jun 5, 2018 21:45 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantDeferred Stock Units · Derivative | 2,188 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-18-035882 · doc4.xml · derivative · entry 4 MCGLYNN MARGARET G · CIK 0001215126 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,188 Underlying: Common Stock · 2,188 shares Expires not disclosed F4 · derivative.exercise_price: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Ms. McGlynn's service on our board of directors, (ii) a change of control of our company and (iii) Ms. McGlynn's disability or death. F2 · price: Upon the vesting of restricted stock units granted to Ms. McGlynn on June 1, 2017, Ms. McGlynn deferred the receipt of 2,188 shares of common stock and received instead 2,188 deferred stock units pursuant to the Company's deferred compensation plan. As a result, Ms. McGlynn is reporting the disposition of 2,188 shares of common stock in exchange for an equal number of deferred stock units. F4 · derivative.exercise_date: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Ms. McGlynn's service on our board of directors, (ii) a change of control of our company and (iii) Ms. McGlynn's disability or death. F4 · derivative.expiration_date: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Ms. McGlynn's service on our board of directors, (ii) a change of control of our company and (iii) Ms. McGlynn's disability or death. Read SEC document |
| June 01, 2018 Filed Jun 5, 2018 21:45 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantStock Option (Right to Buy) · Derivative | 3,229 | $0.00 Strike: $152.74 | $0.00 |
DisclosureSEC source: 0001209191-18-035882 · doc4.xml · derivative · entry 3 MCGLYNN MARGARET G · CIK 0001215126 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,229 Underlying: Common Stock · 3,229 shares Expires 2028-05-31 F3 · derivative.exercise_date: Fully vested. Read SEC document |
| June 01, 2018 Filed Jun 5, 2018 21:45 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Disposition to issuerCommon Stock | 2,188 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-18-035882 · doc4.xml · nonDerivative · entry 2 MCGLYNN MARGARET G · CIK 0001215126 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,925 F2 · price: Upon the vesting of restricted stock units granted to Ms. McGlynn on June 1, 2017, Ms. McGlynn deferred the receipt of 2,188 shares of common stock and received instead 2,188 deferred stock units pursuant to the Company's deferred compensation plan. As a result, Ms. McGlynn is reporting the disposition of 2,188 shares of common stock in exchange for an equal number of deferred stock units. Read SEC document |
| June 01, 2018 Filed Jun 5, 2018 21:45 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantCommon Stock | 1,801 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-035882 · doc4.xml · nonDerivative · entry 1 MCGLYNN MARGARET G · CIK 0001215126 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,113 F1 · shares: Restricted stock unit that vests, subject to certain limited exceptions, on the first anniversary of the grant date. Read SEC document |
| May 16, 2018 Filed May 18, 2018 22:07 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | Exercise / conversionStock Options (right to buy) · Derivative | 10,000 | $0.00 Strike: $3.32 | $0.00 |
DisclosureSEC source: 0001209191-18-031546 · doc4.xml · derivative · entry 3 MCGLYNN MARGARET G · CIK 0001215126 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 10,000 shares Expires 2020-03-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: All of the options were fully vested and exercisable as of May 16, 2018. Read SEC document |
| May 16, 2018 Filed May 18, 2018 22:07 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | SaleCommon Stock | 10,000 | $16.00 | $160,000.00 |
DisclosureSEC source: 0001209191-18-031546 · doc4.xml · nonDerivative · entry 2 MCGLYNN MARGARET G · CIK 0001215126 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,814 F1 · kind: The exercise of stock options and subsequent sale of common stock were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 9, 2018. Read SEC document |
| May 16, 2018 Filed May 18, 2018 22:07 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | Exercise / conversionCommon Stock | 10,000 | $3.32 | $33,200.00 |
DisclosureSEC source: 0001209191-18-031546 · doc4.xml · nonDerivative · entry 1 MCGLYNN MARGARET G · CIK 0001215126 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,814 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 31, 2018 Filed Apr 3, 2018 18:42 UTC | Air Products & Chemicals, Inc. APD · Entity 2983 | GrantPhantom Stock · Derivative | 208.4442 | $158.18 Strike: $0.00 | $32,971.70 |
DisclosureSEC source: 0001225208-18-007092 · doc4.xml · derivative · entry 1 MCGLYNN MARGARET G · CIK 0001215126 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,935.7127 Underlying: Common Stock · 208.4442 shares Expires not disclosed F1 · security: Phantom deferred stock units (Units) acquired under the Air Products Stock Account of the issuer's Deferred Compensation Program for Directors, of the Company's Long-Term Incentive Plan (the Plan). F2 · derivative.exercise_price: Not applicable to this security F3 · derivative.exercise_date: These units are payable in the form of shares of common Stock equal in number to the units, at the time elected by the reporting person, which is generally after service on the issuer's Board of Directors ends. Units may be paid in a lump sum or up to ten installments as elected by the reporting person in advance. F3 · derivative.expiration_date: These units are payable in the form of shares of common Stock equal in number to the units, at the time elected by the reporting person, which is generally after service on the issuer's Board of Directors ends. Units may be paid in a lump sum or up to ten installments as elected by the reporting person in advance. Read SEC document |
| March 02, 2018 Filed Mar 5, 2018 23:13 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $81.54 | $0.00 |
DisclosureSEC source: 0001209191-18-016827 · doc4.xml · derivative · entry 3 MCGLYNN MARGARET G · CIK 0001215126 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2023-05-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Fully vested. Read SEC document |
| March 02, 2018 Filed Mar 5, 2018 23:13 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 10,000 | $170.00 | $1,700,000.00 |
DisclosureSEC source: 0001209191-18-016827 · doc4.xml · nonDerivative · entry 2 MCGLYNN MARGARET G · CIK 0001215126 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,312 F1 · kind: Transaction made pursuant to Ms. McGlynn's company approved trading plan under Rule 10b5-1. Read SEC document |
| March 02, 2018 Filed Mar 5, 2018 23:13 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 10,000 | $81.54 | $815,400.00 |
DisclosureSEC source: 0001209191-18-016827 · doc4.xml · nonDerivative · entry 1 MCGLYNN MARGARET G · CIK 0001215126 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,312 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 25, 2018 Filed Jan 29, 2018 19:13 UTC | Air Products & Chemicals, Inc. APD · Entity 2983 | GrantPhantom Stock · Derivative | 863 | $174.00 Strike: $0.00 | $150,162.00 |
DisclosureSEC source: 0001225208-18-001731 · doc4.xml · derivative · entry 1 MCGLYNN MARGARET G · CIK 0001215126 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,727.2685 Underlying: Common Stock · 863 shares Expires not disclosed F1 · security: Phantom deferred stock units (Units) acquired under the Air Products Stock Account of the issuer's Deferred Compensation Program for Directors, of the Company's Long-Term Incentive Plan (the Plan). F2 · derivative.exercise_price: Not applicable to this security F3 · derivative.exercise_date: These units are payable in the form of shares of common Stock equal in number to the units, at the time elected by the reporting person, which is generally after service on the issuer's Board of Directors ends. Units may be paid in a lump sum or up to ten installments as elected by the reporting person in advance. F3 · derivative.expiration_date: These units are payable in the form of shares of common Stock equal in number to the units, at the time elected by the reporting person, which is generally after service on the issuer's Board of Directors ends. Units may be paid in a lump sum or up to ten installments as elected by the reporting person in advance. Read SEC document |
| January 23, 2018 Filed Jan 24, 2018 22:35 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $59.55 | $0.00 |
DisclosureSEC source: 0001209191-18-005206 · doc4.xml · derivative · entry 6 MCGLYNN MARGARET G · CIK 0001215126 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2022-05-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Fully vested. Read SEC document |
| January 23, 2018 Filed Jan 24, 2018 22:35 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 10,000 | $165.00 | $1,650,000.00 |
DisclosureSEC source: 0001209191-18-005206 · doc4.xml · nonDerivative · entry 4 MCGLYNN MARGARET G · CIK 0001215126 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,217 F1 · kind: Transaction made pursuant to Ms. MsGlynn's company-approved trading plan under Rule 10b5-1. Read SEC document |
| January 23, 2018 Filed Jan 24, 2018 22:35 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 10,000 | $59.55 | $595,500.00 |
DisclosureSEC source: 0001209191-18-005206 · doc4.xml · nonDerivative · entry 3 MCGLYNN MARGARET G · CIK 0001215126 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,217 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 22, 2018 Filed Jan 24, 2018 22:35 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $59.55 | $0.00 |
DisclosureSEC source: 0001209191-18-005206 · doc4.xml · derivative · entry 5 MCGLYNN MARGARET G · CIK 0001215126 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2022-05-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Fully vested. Read SEC document |
| January 22, 2018 Filed Jan 24, 2018 22:35 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 10,000 | $160.00 | $1,600,000.00 |
DisclosureSEC source: 0001209191-18-005206 · doc4.xml · nonDerivative · entry 2 MCGLYNN MARGARET G · CIK 0001215126 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,217 F1 · kind: Transaction made pursuant to Ms. MsGlynn's company-approved trading plan under Rule 10b5-1. Read SEC document |
| January 22, 2018 Filed Jan 24, 2018 22:35 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 10,000 | $59.55 | $595,500.00 |
DisclosureSEC source: 0001209191-18-005206 · doc4.xml · nonDerivative · entry 1 MCGLYNN MARGARET G · CIK 0001215126 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,217 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 31, 2017 Filed Jan 2, 2018 20:40 UTC | Air Products & Chemicals, Inc. APD · Entity 2983 | GrantPhantom Stock · Derivative | 200.2899 | $163.67 Strike: $0.00 | $32,781.45 |
DisclosureSEC source: 0001225208-18-000060 · doc4.xml · derivative · entry 1 MCGLYNN MARGARET G · CIK 0001215126 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,864.2685 Underlying: Common Stock · 200.2899 shares Expires not disclosed F1 · security: Phantom deferred stock units (Units) acquired under the Air Products Stock Account of the issuer's Deferred Compensation Program for Directors, of the Company's Long-Term Incentive Plan (the Plan). F2 · derivative.exercise_price: Not applicable to this security F3 · derivative.exercise_date: These units are payable in the form of shares of common Stock equal in number to the units, at the time elected by the reporting person, which is generally after service on the issuer's Board of Directors ends. Units may be paid in a lump sum or up to ten installments as elected by the reporting person in advance. F3 · derivative.expiration_date: These units are payable in the form of shares of common Stock equal in number to the units, at the time elected by the reporting person, which is generally after service on the issuer's Board of Directors ends. Units may be paid in a lump sum or up to ten installments as elected by the reporting person in advance. Read SEC document |
| September 30, 2017 Filed Oct 2, 2017 18:50 UTC | Air Products & Chemicals, Inc. APD · Entity 2983 | GrantPhantom Stock · Derivative | 215.285 | $151.32 Strike: $0.00 | $32,576.93 |
DisclosureSEC source: 0001225208-17-015542 · doc4.xml · derivative · entry 1 MCGLYNN MARGARET G · CIK 0001215126 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,663.9786 Underlying: Common Stock · 215.285 shares Expires not disclosed F1 · security: Phantom deferred stock units (Units) acquired under the Air Products Stock Account of the issuer's Deferred Compensation Program for Directors, of the Company's Long-Term Incentive Plan (the Plan). F2 · derivative.exercise_price: Not applicable to this security F3 · derivative.exercise_date: These units are payable in the form of shares of common Stock equal in number to the units, at the time elected by the reporting person, which is generally after service on the issuer's Board of Directors ends. Units may be paid in a lump sum or up to ten installments as elected by the reporting person in advance. F3 · derivative.expiration_date: These units are payable in the form of shares of common Stock equal in number to the units, at the time elected by the reporting person, which is generally after service on the issuer's Board of Directors ends. Units may be paid in a lump sum or up to ten installments as elected by the reporting person in advance. Read SEC document |
| June 30, 2017 Filed Jul 5, 2017 19:51 UTC | Air Products & Chemicals, Inc. APD · Entity 2983 | GrantPhantom Stock · Derivative | 223.451 | $144.84 Strike: $0.00 | $32,364.64 |
DisclosureSEC source: 0001225208-17-012141 · doc4.xml · derivative · entry 1 MCGLYNN MARGARET G · CIK 0001215126 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,448.6936 Underlying: Common Stock · 223.451 shares Expires not disclosed F1 · security: Phantom deferred stock units (Units) acquired under the Air Products Stock Account of the issuer's Deferred Compensation Program for Directors, of the Company's Long-Term Incentive Plan (the Plan). F2 · derivative.exercise_price: Not applicable to this security F3 · derivative.exercise_date: These units are payable in the form of shares of common Stock equal in number to the units, at the time elected by the reporting person, which is generally after service on the issuer's Board of Directors ends. Units may be paid in a lump sum or up to ten installments as elected by the reporting person in advance. F3 · derivative.expiration_date: These units are payable in the form of shares of common Stock equal in number to the units, at the time elected by the reporting person, which is generally after service on the issuer's Board of Directors ends. Units may be paid in a lump sum or up to ten installments as elected by the reporting person in advance. Read SEC document |
| June 13, 2017 Filed Jun 15, 2017 20:17 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | GrantStock Options (right to buy) · Derivative | 16,236 | $0.00 Strike: $8.60 | $0.00 |
DisclosureSEC source: 0001209191-17-040114 · doc4.xml · derivative · entry 2 MCGLYNN MARGARET G · CIK 0001215126 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,236 Underlying: Common Stock · 16,236 shares Expires 2027-06-13 F1 · derivative.exercise_date: One hundred percent of the shares subject to this option will vest and become exercisable on the date of the annual meeting of the stockholders of the issuer to be held in 2018. Read SEC document |
| June 13, 2017 Filed Jun 15, 2017 20:17 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | GrantCommon Stock | 5,814 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-040114 · doc4.xml · nonDerivative · entry 1 MCGLYNN MARGARET G · CIK 0001215126 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,814 Read SEC document |
| June 13, 2017 Filed Jun 16, 2017 21:02 UTC Amendment | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | GrantCommon Stock | 5,814 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-040582 · doc4a.xml · nonDerivative · entry 1 MCGLYNN MARGARET G · CIK 0001215126 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,814 F1 · balance_after: This Form 4 amendment corrects the reporting person's amount of securities beneficially owned following the reported transaction. Read SEC document |
| June 01, 2017 Filed Jun 5, 2017 21:59 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,295 | $0.00 Strike: $125.71 | $0.00 |
DisclosureSEC source: 0001209191-17-037911 · doc4.xml · derivative · entry 2 MCGLYNN MARGARET G · CIK 0001215126 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,295 Underlying: Common Stock · 5,295 shares Expires 2027-05-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Fully vested. Read SEC document |
| June 01, 2017 Filed Jun 5, 2017 21:59 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantCommon Stock | 2,188 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-037911 · doc4.xml · nonDerivative · entry 1 MCGLYNN MARGARET G · CIK 0001215126 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,217 F1 · shares: Restricted stock unit award that vests, subject to certain limited exceptions, on the first anniversary of the grant date. Read SEC document |
| March 31, 2017 Filed Apr 4, 2017 18:18 UTC | Air Products & Chemicals, Inc. APD · Entity 2983 | GrantPhantom Stock · Derivative | 202.5553 | $136.78 Strike: $0.00 | $27,705.51 |
DisclosureSEC source: 0001225208-17-007280 · doc4.xml · derivative · entry 1 MCGLYNN MARGARET G · CIK 0001215126 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,225.2426 Underlying: Common Stock · 202.5553 shares Expires not disclosed F1 · security: Phantom deferred stock units (Units) acquired under the Air Products Stock Account of the issuer's Deferred Compensation Program for Directors, of the Company's Long-Term Incentive Plan (the Plan). F2 · derivative.exercise_price: Not applicable to this security F3 · derivative.exercise_date: These units are payable in the form of shares of common Stock equal in number to the units, at the time elected by the reporting person, which is generally after service on the issuer's Board of Directors ends. Units may be paid in a lump sum or up to ten installments as elected by the reporting person in advance. F3 · derivative.expiration_date: These units are payable in the form of shares of common Stock equal in number to the units, at the time elected by the reporting person, which is generally after service on the issuer's Board of Directors ends. Units may be paid in a lump sum or up to ten installments as elected by the reporting person in advance. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.